source
- F2G and Shionogi report positive Phase 3 results for antifungal candidate olorofimF2G and Shionogi announced that their joint antifungal candidate, olorofim, met the primary endpoints in a Phase 3 trial. The data were released Thursday morning and showed the drug performed compa…
- Kardigan secures $400 million IPO to fund three clinical-stage cardiovascular candidatesKardigan, a New Jersey biotech focused on heart disease, announced it raised $400 million in a Nasdaq initial public offering. The capital will be directed toward advancing three clinical-stage dr…